GSK has snagged FDA approval for its 5-in-1 meningococcal vaccine, propelling it to a familiar position: rivaling Pfizer.

GlaxoSmithKline Pharmaceuticals Ltd reported an 18% revenue increase to ₹946 crore for Q3 ended December 31, 2024, with a ...

(Alliance News) - Hedge fund Citadel has made a GBP305 million bet against pharmaceuticals firm GSK PLC, the biggest short position against the company in more than a decade, according to the ...

Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

The world’s most profitable hedge fund has started betting against shares in GSK (GSK), the first significant short on the FTSE 100 drugmaker’s ...

Dilip Buildcon’s profit (attributable to owners of the company) for the third quarter of the financial year 2025 (Q3 FY25) ...

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The ...

GlaxoSmithKline Pharmaceuticals reports a five-fold jump in net profit for the third quarter ending December 31, 2024, ...

Today, majors across segments including Parle Industries, Easy Trip Planners, Bajaj Consumer Care, Aditya Birla Fashion & ...